一种针对多发性骨髓瘤的抗体-药物结合物,由多臂链接器制备
Yueh-Hsiang Yu1, Wei-Ting Tian1, Cédric Grauffel1
1Immunwork, Inc., Academia Rd., Sec. 1, Nangang, Taipei, 115, Taiwan.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|March 13, 2024
概括
一种新型抗体-药物结合物TE-1146通过将细胞毒性莱纳利多米德直接输送到瘤细胞来增强多发性骨髓瘤治疗效果,比现有疗法提高了疗效和安全性.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 生物结合化学 生物结合化学
背景情况:
- 用抗CD38药物达拉图姆巴和莱纳利多米德治疗多发性骨髓瘤面临复发和严重副作用的挑战.
- 目前的疗法往往缺乏向性治疗,限制了疗效,增加了毒性.
研究的目的:
- 开发一种抗体-药物合物 (TE-1146) 以提高多发性骨髓瘤治疗的有效性和安全性.
- 为了针对性地传递,将特定位点的联结列纳利多米德与重新配置的达拉图穆马布抗体.
主要方法:
- 使用HighDAR平台开发TE-1146,用于对多个lenalidomide分子进行特定位点的结合.
- 使用含有maleimide的链接器和重新配置的daratumumab与Zn2+结合用于药物捆绑.
主要成果:
- TE-1146证明了完整的细胞吸收到表达CD38的多发性髓瘤细胞中.
- 内部化TE-1146释放了列纳利多米德,与组合疗法相比,导致瘤细胞杀伤的增强.
- 结合物精确地将莱纳利多米德传递到向细胞,与未结合的莱纳利多米德或单独的达拉图马布不同.
结论:
- TE-1146显示出作为治疗多发性骨髓瘤的改进治疗策略的巨大潜力.
- 特定抗体-药物结合物可以克服传统组合疗法的局限性.
- 有针对性的细胞毒药物治疗增强了抗癌功效,并可能降低系统性毒性.
更多相关视频
11:58Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
Published on: March 8, 2018
7.6K
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
12.1K
相关概念视频
01:31Hybridoma Technology
14.7K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.7K
00:49Ligand Binding and Linkage
4.8K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.8K